Is Kymera Therapeutics, Inc. KYMR stock Halal to invest in?

No, as of September 2026, Kymera Therapeutics, Inc. stock (KYMR) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. To qualify as Halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Kymera Therapeutics, Inc. currently does not meet the threshold for the non-permissible income screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Kymera Therapeutics, Inc. and discover Shariah compliant alternatives among the Halal stocks in the Tabadulat app.

How often is Kymera Therapeutics, Inc. KYMR reviewed for Shariah compliance?

Tabadulat reviews Kymera Therapeutics, Inc. KYMR for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Kymera Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Kymera Therapeutics, Inc. KYMR pass the AAOIFI Non Permissible Income criteria?

No, as of September 2026, Kymera Therapeutics, Inc. stock (KYMR) does not pass the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or Riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Kymera Therapeutics, Inc.'s income from non-permissible sources currently exceeds this 5% ceiling, which makes the stock non-compliant on this criterion regardless of how it performs on the other screens. The screen is reassessed monthly, so the status can change when the company releases new financial statements.

Does Kymera Therapeutics, Inc. KYMR pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, Kymera Therapeutics, Inc. stock (KYMR) passes the AAOIFI interest-bearing investments screen. This screen looks at where the company parks its cash: conventional deposits, bonds, treasury bills and money-market funds all earn Riba, so AAOIFI caps them at 30% of market capitalisation. Kymera Therapeutics, Inc. stays inside that cap in the latest screening. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Kymera Therapeutics, Inc. KYMR pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Kymera Therapeutics, Inc. stock (KYMR) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar Riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Kymera Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Kymera Therapeutics, Inc. KYMR stock?

Kymera Therapeutics, Inc. (KYMR) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (Tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a Halal investment. If Kymera Therapeutics, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Kymera Therapeutics, Inc. KYMR pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Kymera Therapeutics, Inc. stock (KYMR) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Kymera Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Kymera Therapeutics (KYMR) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

Kymera Therapeutics, Inc. (KYMR) is not Shariah compliant in the September 2026 AAOIFI screening: it fails the non-permissible income screen. Tabadulat re-screens KYMR monthly, and a stock can return to compliance when new financial reports change its ratios.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

225

Website:

https://www.kymeratx.com

Market cap:

P/E ratio:

Dividend yield:

52-week range:

Data as of:

Screening history:

September 2026: FAIL

Kymera Therapeutics is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have traditionally been considered "undruggable." Kymera's primary function is to leverage its proprietary drug discovery platform to design small molecules that harness the cell's natural protein degradation processes, redirecting them to undesirable proteins and proteins involved in various diseases like cancer and immune-inflammatory conditions. Before any of that matters to a Muslim investor, one question comes first: is Kymera Therapeutics stock Halal?

Is Kymera Therapeutics Shariah compliant?

The Shariah case on a technology company like Kymera Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Kymera Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: Kymera Therapeutics currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Kymera Therapeutics' income Halal?

No. Kymera Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does Kymera Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has KYMR re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.